Connexion
M'inscrire

Votre recherche

Filtres

Project précédent
Projet suivant
Nous verifions auprès de chaque centre si des nouvelles informations sont disponibles

UPCC 16213

Tace with or without sbrt as bridging therapy for pre-transplant hcc patients
Source : Importé depuis le centre

Référence clinicaltrials.gov: NCT01918683
Recrutement fermé
Dernière modification : 2026/01/28
Type de recherche

Interventionnel


Population cible

Condition médicale (spécialité visée)

Donnée non disponible

Profil des participants

Limites d'âge
minimum : 18 ans
Sexe(s) des participants

ALL

Source : Importé depuis le centre

Critères de sélection

Critères d'inclusion

Inclusion Criteria:

* Patient capable of giving informed consent
* Patient diagnosed with hepatocellular carcinoma and listed or recommended to be listed for orthotopic liver transplantation at the participating institution
* Age \> 18 years old
* Meets clinical criteria for eligibility for TACE to the target lesion per Interventional Radiology
* Childs' Class A or B7
* Eastern Clinical Oncology Group performance status 0 or 1

Exclusion Criteria:

* Prior radiotherapy to the upper abdomen or radioembolization of the liver
* Prior TACE to the target lesion, RFA, or liver transplant
* Active GI bleed within 2 weeks of study enrollment
* Active GI ulcer disease within 4 weeks of study enrollment
* Ascites refractory to medical therapy
* Contraindication to receiving radiotherapy or TACE
* Complete obstruction of portal venous flow to the segment of liver that includes the target lesion
* Contraindication to both contrast enhanced MRI and contrast enhanced CT (i.e. unable to undergo follow-up imaging or SBRT treatment planning)
* Women who are pregnant
* Participation in another concurrent treatment protocol

Source : Importé depuis le centre

Thérapie ou Intervention proposée

Cohortes
Nom Condition médicale Traitement État du recrutement
A -Tace alone A - TACE alone (control group, current practice and treatment) Donnée non disponible
  • Inconnu
  • B - Tace combined with SBRT B- TACE combined with SBRT (experimental group). Donnée non disponible
  • Inconnu
  • A -Tace alone
    État du recrutement
    unknown
    B - Tace combined with SBRT
    État du recrutement
    unknown
    Données à jour depuis : 28 janvier 2026

    Description de l'étude

    Résumé de l'étude

    This trial is designed to be the initial prospective pilot investigation of the effectiveness of combined SBRT and TACE as bridging therapy for HCC patients awaiting liver transplanation. No prospective clinical trials regarding the combination of TACE and SBRT in pre-transplant population have been performed. We propose the trial be conducted as a pilot clinical trial with the goal of enrolling 40 patients into each arm

    Source : Importé depuis le centre

    The purpose of this study is to determine whether the combination of stereotatic body radiotherapy (SBRT) tand transarterial chemoembolization (TACE) is an effective "bridging therapy" for patients hepatocellular carcinoma (HCC) of the liver awaiting transplantation.

    Source : Importé depuis le centre

    Sites

    Centres participants

      3 centres
    • ABRAMSON CANCER CENTER OF THE UNIVERSITY OF PENNSYLVANIA

      Philadelphia

      PENNSYLVANIA, UNITED STATES

      Recrutement local
      État du recrutement: FERMÉ
    • LOYOLA UNIVERSITY MEDICAL CENTER

      Maywood

      ILLINOIS, UNITED STATES

      Recrutement local
      État du recrutement: FERMÉ
    • OREGON HEALTH & SCIENCE UNIVERSITY

      Portland

      OREGON, UNITED STATES

      Recrutement local
      État du recrutement: FERMÉ

    Dernière modification : 28 janvier 2026
    Données à jour depuis : 30 jan.
    Origine des données : clinicaltrials.gov
    Référence clinicaltrials.gov: NCT01918683